Laboratorios RichmondC.I.F Past Earnings Performance
Past criteria checks 2/6
Laboratorios RichmondC.I.F's earnings have been declining at an average annual rate of -36.2%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 42.1% per year. Laboratorios RichmondC.I.F's return on equity is 7%, and it has net margins of 10%.
Key information
-36.2%
Earnings growth rate
-36.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 42.1% |
| Return on equity | 7.0% |
| Net Margin | 10.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Laboratorios RichmondC.I.F makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 35,583 | 3,552 | 12,532 | 0 |
| 31 Mar 24 | 35,303 | -3,040 | 14,351 | 0 |
| 31 Dec 23 | 39,028 | -10,851 | 15,011 | 0 |
| 30 Sep 23 | 71,368 | -6,536 | 27,064 | 0 |
| 30 Jun 23 | 72,371 | -4,906 | 27,446 | 0 |
| 31 Mar 23 | 72,109 | 286 | 23,001 | 0 |
| 31 Dec 22 | 57,518 | 509 | 17,935 | 0 |
| 30 Sep 22 | 45,778 | 3,055 | 10,466 | 0 |
| 30 Jun 22 | 48,279 | 3,327 | 8,716 | 0 |
| 31 Mar 22 | 36,224 | 1,899 | 6,325 | 0 |
| 31 Dec 21 | 32,366 | 1,152 | 5,110 | 0 |
| 30 Sep 21 | 19,727 | 290 | 3,683 | 0 |
| 30 Jun 21 | 12,651 | 635 | 3,090 | 0 |
| 31 Mar 21 | 10,091 | 584 | 2,515 | 0 |
| 31 Dec 20 | 9,330 | 734 | 2,218 | 0 |
| 30 Sep 20 | 7,680 | 486 | 2,011 | 0 |
| 30 Jun 20 | 6,978 | 319 | 1,873 | 0 |
| 31 Mar 20 | 6,140 | 235 | 1,701 | 0 |
| 31 Dec 19 | 5,303 | 159 | 1,512 | 0 |
| 30 Sep 19 | 3,902 | -84 | 1,339 | 0 |
| 30 Jun 19 | 3,343 | -284 | 1,256 | 0 |
| 31 Mar 19 | 3,013 | -414 | 1,161 | 0 |
| 31 Dec 18 | 2,795 | -332 | 1,065 | 0 |
| 30 Sep 18 | 2,820 | -306 | 1,064 | 0 |
| 30 Jun 18 | 2,296 | -125 | 883 | 0 |
| 31 Mar 18 | 1,904 | 13 | 706 | 0 |
| 31 Dec 17 | 1,591 | 49 | 588 | 0 |
| 30 Sep 17 | 1,048 | 100 | 287 | 0 |
| 30 Jun 17 | 988 | 103 | 264 | 0 |
| 31 Mar 17 | 912 | 106 | 242 | 0 |
| 31 Dec 16 | 856 | 95 | 214 | 0 |
| 30 Sep 16 | 653 | 28 | 215 | 0 |
| 30 Jun 16 | 568 | 14 | 197 | 0 |
| 31 Mar 16 | 504 | 12 | 170 | 0 |
| 31 Dec 15 | 446 | 6 | 154 | 0 |
| 30 Sep 15 | 407 | 17 | 126 | 0 |
| 30 Jun 15 | 384 | 15 | 113 | 0 |
| 31 Mar 15 | 361 | 12 | 106 | 0 |
| 31 Dec 14 | 347 | 6 | 104 | 0 |
| 30 Sep 14 | 296 | 0 | 106 | 0 |
| 30 Jun 14 | 273 | -11 | 102 | 0 |
| 31 Mar 14 | 259 | -12 | 99 | 0 |
| 31 Dec 13 | 260 | 0 | 96 | 0 |
Quality Earnings: RICHD has a large one-off gain of ARS1.3B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: RICHD became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RICHD has become profitable over the past 5 years, growing earnings by -36.2% per year.
Accelerating Growth: RICHD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RICHD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.3%).
Return on Equity
High ROE: RICHD's Return on Equity (7%) is considered low.